However, one of the common adverse effects of β2-agonists is hypokalemia (relative risk, 6.07; 95% confidence interval, 4.00 to 9.20) [1], which is due to an increase in uptake of extracellular potassium by promoting insulin secretion in pancreatic islets with β2 adrenoceptor stimulation [2]. Here, INS is linked to Hypokalemia.